European Journal of Heart Failure最新文献

{"title":"High prevalence of wild‐type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study","authors":"Alberto Aimo, Giuseppe Vergaro, Maria Concetta Pastore, Daniela Tomasoni, Vincenzo Castiglione, Riccardo Saro, Elisa Zaro, Antonio Maria Sammartino, Elisa Giacomin, Matteo Serenelli, Alberto Cipriani, Aldostefano Porcari, Andrea Di Lenarda, Marco Metra, Gianfranco Sinagra, Matteo Cameli, Marco Merlo, Michele Emdin","doi":"10.1002/ejhf.70030","DOIUrl":"https://doi.org/10.1002/ejhf.70030","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"38 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144928251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.","authors":"Karina V Bunting, Asgher Champsi, Simrat K Gill, Khalil Saadeh, A John Camm, Mary Stanbury, Sandra Haynes, Jonathon N Townend, Richard P Steeds, Dipak Kotecha","doi":"10.1002/ejhf.70022","DOIUrl":"https://doi.org/10.1002/ejhf.70022","url":null,"abstract":"<p><strong>Aims: </strong>To compare the effect of digoxin versus beta-blockers on left ventricular function, in patients with permanent atrial fibrillation (AF) and symptoms of heart failure within the RATE-AF randomized trial.</p><p><strong>Methods and results: </strong>Blinded echocardiograms were performed at baseline and 12-month follow-up using a pre-defined imaging protocol and the index-beat approach. The change in systolic and diastolic function was assessed, stratified by left ventricular ejection fraction (LVEF). Overall, 145 patients completed follow-up, with median age 75 years (interquartile range 69-82) and 44% women. In 119 patients with baseline LVEF ≥50%, a significantly greater improvement in systolic function was noted in patients randomized to low-dose digoxin versus beta-blockers: adjusted mean difference for LVEF 2.3% (95% confidence interval [CI] 0.3-4.2; p = 0.021), s' 1.1 cm/s (95% CI 1.0-1.2; p = 0.001) and stroke volume 6.5 ml (95% CI 0.4-12.6; p = 0.037), with no difference in global longitudinal strain (p = 0.11) or any diastolic parameters. There were no significant differences between groups for patients with LVEF 40-49% and <40%. Digoxin reduced N-terminal pro-B-type natriuretic peptide compared to beta-blockers (geometric mean difference 0.77; 95% CI 0.64-0.92; p = 0.004), improved New York Heart Association functional class (odds ratio [OR] 11.3, 95% CI 4.3-29.8; p < 0.001) and modified European Heart Rhythm Association arrhythmia symptom class (OR 4.91, 95% CI 2.36-10.23; p < 0.001), with substantially less adverse events (incident rate ratio 0.21, 95% CI 0.13-0.31; p < 0.001). There were no interactions between treatment effects and baseline LVEF for these outcomes (interaction p = 0.62, 0.49, 0.07 and 0.13, respectively).</p><p><strong>Conclusions: </strong>Low-dose digoxin in patients with symptoms of heart failure, preserved LVEF and permanent AF leads to a significantly greater improvement in systolic function compared to treatment with beta-blockers.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher hospital volume is associated with lower mortality for patients with cardiogenic shock and mechanical circulatory support","authors":"Angela Dettling, Caroline Kellner, Jonas Sundermeyer, Benedikt N. Beer, Lisa Besch, Marvin Kriz, Stefan Kluge, Paulus Kirchhof, Stefan Blankenberg, Benedikt Schrage","doi":"10.1002/ejhf.70025","DOIUrl":"https://doi.org/10.1002/ejhf.70025","url":null,"abstract":"AimsMortality for cardiogenic shock (CS) remains high. To improve outcomes, centralization of treatment in specialized centres, especially those with expertise in mechanical circulatory support (MCS), has been recommended. High‐volume centres may be able to provide standardized, better care. We analysed associations between centre volume and outcomes in Germany, a large country with multiple types of CS centres.Methods and resultsBased on data from all CS patients treated in Germany from 2017–2021, the association between annual CS/MCS hospital volume and in‐hospital mortality was assessed using adjusted Cox‐regression, and spline plots were used to assess case thresholds. Overall, 220 223 CS patients underwent treatment at 1232 hospitals; 435/1232 (35%) of these performed MCS therapy, although only few hospitals (60/435, 14%) performed &gt;25 MCS cases per year on average. Treatment at hospitals with a higher annual volume of CS and MCS cases was associated with a significantly lower mortality risk as compared to hospitals with a lower volume (upper third vs. lower two‐thirds; CS: hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.91–0.94; <jats:italic>p</jats:italic> &lt; 0.001; MCS: HR 0.80, 95% CI 0.76–0.84; <jats:italic>p</jats:italic> &lt; 0.001). These associations were continuous without a detectable ceiling effect, with spline plots suggesting case thresholds of at least 90 CS cases/25 MCS cases per year.ConclusionsCare for patients with CS treated with and without MCS is associated with lower in‐hospital mortality in hospitals that manage high volumes of CS and MCS. This analysis indicates that centralization of CS care in specialized centres treating high volumes of patients with CS and MCS might improve outcomes.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"9 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left ventricular ejection fraction and benefit of tricuspid valve interventions - insights from the international TRIGISTRY.","authors":"Gregor Heitzinger, Julien Dreyfus, Varius Dannenberg, Yan Topilsky, Giovanni Benfari, Nina Ajmone Marsan, Maurizio Taramasso, Giulio Russo, Yohann Bohbot, Christos Iliadis, Marcel Weber, Luis Nombela-Franco, Andrea Eixerés-Esteve, Baptiste Bazire, Bernard Iung, Jean-François Obadia, Rodrigo Estevez Loureiro, Elisabeth Riant, Erwan Donal, Gilbert Habib, Yoan Lavie-Badie, Jörg Hausleiter, Lucas Stolz, Luigi Badano, Thierry Le Tourneau, Augustin Coisne, Thomas Modine, Fabien Praz, Jose Luis Zamorano, Ralph Stephan von Bardeleben, Rebecca T Hahn, Neil Fam, Horst Sievert, Denisa Muraru, Mariana Adamo, Samuel Heuts, Mohammed Nejjari, Vincent Chan, Michele De Bonis, Manuel Carnero-Alcazar, Volker Rudolph, Juan Crestanello, Philipp Lurz, Jeroen Bax, Roja Gauda, Jordan Bernick, George A Wells, Francesco Maisano, Maurice Enriquez-Sarano, Philipp Bartko, David Messika-Zeitoun","doi":"10.1002/ejhf.3797","DOIUrl":"https://doi.org/10.1002/ejhf.3797","url":null,"abstract":"<p><strong>Aims: </strong>The impact of treatment for tricuspid regurgitation (TR) across different levels of left ventricular ejection fraction (LVEF) remains uncertain. This study aimed to compare the outcomes of surgical and transcatheter tricuspid valve interventions (TTVI) to conservative (medical) management across LVEF categories.</p><p><strong>Methods and results: </strong>Patients with severe isolated TR from the TRIGISTRY, a multicentre international registry, were categorized based on LVEF (preserved ejection fraction [pEF]: ≥50%, mildly reduced ejection fraction [mrEF]: 41-49%, and reduced ejection fraction [rEF]: ≤40%). We assessed the impact of treatment modality and procedural success (mild-to-moderate or lower residual TR) on 2-year survival within each LVEF category. Among 2384 patients, 1383 had pEF, 400 had mrEF, and 601 had rEF. Compared to conservative management, surgery (p < 0.0005) and TTVI (p < 0.0001) were associated with a survival benefit in patients with pEF. No significant survival advantage was observed in patients with mrEF (p = 0.28 for both), nor in those with rEF (p = 0.76 and p = 0.22, respectively). Similar results were obtained when surgical and transcatheter interventions were grouped (p < 0.0001, p = 0.17 and p = 0.29 in patients with pEF, mrEF and rEF, respectively). Patients with residual TR after TTVI exhibited a trend toward worse survival compared to those managed conservatively across all LVEF categories (p = 0.47, p = 0.33 and p = 0.008 in pEF, mrEF and rEF, respectively).</p><p><strong>Conclusions: </strong>Transcatheter tricuspid valve intervention, whether surgical or transcatheter-based, was associated with improved survival in patients with pEF but not in those with mrEF or rEF. Residual TR remained a significant prognostic factor across the entire LVEF spectrum. These findings highlight the need for careful patient selection when considering TTVI in individuals with rEF.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why do people with heart failure die? Rationale and design of the RHYTHM-HF study","authors":"Simon A.S. Beggs,&nbsp;Mark C. Petrie,&nbsp;Sylvia Wright,&nbsp;Derek T. Connelly,&nbsp;Gary A. Wright,&nbsp;Iain Squire,&nbsp;Theresa A. McDonagh,&nbsp;Luke McSpadden,&nbsp;Chunlan Jiang,&nbsp;Kyungmoo Ryu,&nbsp;John J.V. McMurray,&nbsp;Roy S. Gardner","doi":"10.1002/ejhf.70014","DOIUrl":"10.1002/ejhf.70014","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aim of RHYTHM-HF is to provide novel insights into the causes and mechanisms of death in near-consecutive patients discharged following a heart failure hospitalization using data from insertable cardiac monitors (ICMs) and autopsy examinations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>RHYTHM-HF enrolled an unselected, prospective, near-consecutive, observational cohort of 257 patients admitted to hospital with a primary diagnosis of decompensated heart failure over a 2-year period. Potential participants were screened using N-terminal pro-B-type natriuretic peptide and echocardiography. All enrolled participants received a subcutaneously implanted ICM (which provides long-term cardiac rhythm recordings) before hospital discharge. An optional sub-study invited participants to consent prospectively to autopsy in the event of death. Following hospital discharge, there was no physical follow-up, with longitudinal ICM data obtained by remote upload. Participants were followed for up to 4 years. Data permitting determination of the cause, mode and mechanism of death were collected, including ICM-derived terminal cardiac rhythm and pathological findings at autopsy. Rigorous stepwise clinical adjudication processes were employed in the study (step 1 using clinical data alone, step 2 using additional post-mortem data, and step 3 using additional terminal rhythm data).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The RHYTHM-HF study is a contemporary natural history study which investigated causes and mechanisms of death in patients with heart failure. It is the largest study to report terminal rhythm data in patients with heart failure, the largest contemporary prospective autopsy study in heart failure, and the only study to describe the interaction between terminal rhythm and pathological cause of death using modern adjudication standards. We anticipate new mechanistic insights into the cause and mode of death in heart failure. These findings will generate hypotheses for future clinical research into reducing death in heart failure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 10","pages":"1918-1926"},"PeriodicalIF":10.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144919052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular outcomes with tirzepatide in heart failure with preserved ejection fraction associated with obesity","authors":"Laurent Fauchier, Lisa Lochon, Thibault Lenormand, Bertrand Pierre, Alexandre Bodin, Mickael Guglieri, Arnaud Bisson","doi":"10.1002/ejhf.70012","DOIUrl":"https://doi.org/10.1002/ejhf.70012","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"54 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144919051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parvovirus B19 – more than a bystander in the prognosis of non‐ischaemic heart failure","authors":"Tobias Harm, Andre Keren, Oliver Borst","doi":"10.1002/ejhf.70008","DOIUrl":"https://doi.org/10.1002/ejhf.70008","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"23 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article ‘Incident heart failure is common and underrecognized in patients with biopsy‐proven metabolic dysfunction‐associated steatotic liver disease’","authors":"Kara Wegermann, Marat Fudim","doi":"10.1002/ejhf.3777","DOIUrl":"https://doi.org/10.1002/ejhf.3777","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"18 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: A post‐hoc analysis of the CLOROTIC trial","authors":"Ambarish Pandey, Matthew W. Segar, Neil Keshvani, Pau Llácer, Jesús Casado, José Luis Morales‐Rull, Francesc Formiga, Luis Manzano, Harriette G.C. Van Spall, Joan Carles Trullàs","doi":"10.1002/ejhf.70002","DOIUrl":"https://doi.org/10.1002/ejhf.70002","url":null,"abstract":"AimsDiuretic resistance (DR) in acute decompensated heart failure (ADHF) is associated with poor outcomes. The CLOROTIC trial demonstrated hydrochlorothiazide (HCTZ) with intravenous furosemide improved weight loss in ADHF. We assessed performance of the BAN‐ADHF DR score and association between DR risk and HCTZ treatment response.Methods and resultsWe included participants from CLOROTIC and assessed BAN‐ADHF performance in identifying lowest net diuretic efficiency phenogroup, as identified with a random forest classifier. Participants were stratified by the BAN‐ADHF score (≤12: low DR risk and &gt;12: high DR risk) to compare treatment effect of HCTZ versus placebo across DR risk. Outcomes were weight change and area under the curve (AUC) of dyspnoea visual analogue scale (VAS) at 72/96 h, fluid loss at 72 h, and 30/90‐day mortality. Among 220 participants (50.9% male, mean age 83 years), the BAN‐ADHF score demonstrated good performance in identifying low net diuretic efficiency phenogroup (area under the receiver operating characteristic curve: 0.81). Weight change and VAS AUC at 72 h was similar across DR risk strata, however, participants with high versus low DR risk had lower fluid loss at 72 h (686 vs. 889 ml, <jats:italic>p</jats:italic> = 0.003), higher 30‐day (11.1% vs. 2.4%, <jats:italic>p</jats:italic> = 0.035) and 90‐day mortality (23.0% vs. 10.6%, <jats:italic>p</jats:italic> = 0.033). The treatment effect of HCTZ (vs. placebo) on weight change was similar across DR risk (<jats:italic>p</jats:italic><jats:sub>int</jats:sub> = 0.75 at 72 h; <jats:italic>p</jats:italic><jats:sub>int</jats:sub> = 0.50 at 96 h). DR risk modified efficacy of HCTZ versus placebo on dyspnoea VAS, with high (vs. low) DR risk having attenuated improvement at 72 h (−236 vs. 476 mm; <jats:italic>p</jats:italic><jats:sub>int</jats:sub> = 0.03) and 96 h (−400 vs. 777 mm; <jats:italic>p</jats:italic><jats:sub>int</jats:sub> = 0.001).ConclusionsThe BAN‐ADHF score demonstrated good performance in identifying DR, and high DR risk was associated with worse outcomes. HCTZ treatment response on weight loss was similar across DR risk, but improvement in dyspnoea with HCTZ was attenuated in high DR risk.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"138 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial","authors":"Markus S. Anker,&nbsp;Amir A. Mahabadi,&nbsp;Matthias Totzeck,&nbsp;Mitra Tewes,&nbsp;Raluca Mincu,&nbsp;Muhammad Shahzeb Khan,&nbsp;Javed Butler,&nbsp;Ulrich Keller,&nbsp;Johann Ahn,&nbsp;Lars Bullinger,&nbsp;Dominik P. Modest,&nbsp;Ulf Landmesser,&nbsp;Lorenz H. Lehmann,&nbsp;Sven Bercker,&nbsp;Ulrich Laufs,&nbsp;Michael Böhm,&nbsp;Bela Merkely,&nbsp;Monika Diek,&nbsp;Tim Heise,&nbsp;Martin Hellmich,&nbsp;Marius Placzek,&nbsp;Tim Friede,&nbsp;Stefan D. Anker,&nbsp;Tienush Rassaf","doi":"10.1002/ejhf.3799","DOIUrl":"10.1002/ejhf.3799","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>End-stage cancer may resemble a heart failure (HF)-like phenotype marked by cardiac wasting, dysfunction, and symptoms such as dyspnoea, congestion, and impaired physical function. The EMPATICC (EMPower the heArt of patients with TermInal Cancer using Cardiac medicines) trial evaluates the safety and efficacy of optimized HF therapy in patients with advanced cancer to improve self-care ability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>EMPATICC is a multicentre, investigator-initiated, randomized, double-blind, controlled, proof-of-concept trial employing a joint cardio-oncology care approach. Patients were randomized 1:1 to optimized HF therapy (sacubitril/valsartan, empagliflozin, ivabradine, ferric carboxymaltose) plus usual care, or usual care alone, for 30 days, followed by a 30-day open-label extension. Eligible patients had stage IV solid tumours (per Union for International Cancer Control), were receiving palliative care, had a 1–6 month life expectancy, and were on optimized analgesia. At baseline, first patients had to meet ≥2 criteria of the following indicating cardiovascular risk: heart rate ≥70 bpm, N-terminal pro-B-type natriuretic peptide ≥600 pg/ml, elevated high-sensitivity troponin, left ventricular ejection fraction &lt;55%, left ventricular mass loss &gt;15%, transferrin saturation &lt;20%, or moderate/high likelihood of HF with preserved ejection fraction (based on the HFA-PEFF score); and they had to meet at least one criterion of the following indicating functional limitation: ≥6 s to walk 4 m, inability to wash ≥3 days of the last 7 days, or symptoms of dyspnoea at rest. Enrolment ended 30 January 2025; 93 patients completed randomization. The primary endpoint is a hierarchical composite (analysed by win ratio): (1) days alive and able to wash, (2) 4 m walking ability, and (3) patient global assessment of well-being.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>EMPATICC evaluates whether HF therapy can improve function and well-being in advanced cancer, potentially reshaping care in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 10","pages":"1905-1917"},"PeriodicalIF":10.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}